Archive for the ‘American Association for Cancer Research’ Category
When journals learn papers are problematic, how long does it take them to act?
We recently had a chance to find out as part of our continuing coverage of the case of Anil Jaiswal at the University of Maryland, who’s retracted 15 papers (including two new ones we recently identified), and has transitioned out of cancer research. Here’s what happened.
As part of a public records request related to the investigation, we received letters that the University of Maryland sent to 11 journals regarding 26 “compromised” papers co-authored by Jaiswal, four of which had been retracted by the time of the letter. The letters were dated between August and September 2016 (and one in February) — although, in some cases, the journals told us they received the letter later. Since that date, three journals have retracted nine papers and corrected another, waiting between four and six months to take action. One journal published an editorial note of concern within approximately two months after the university letter.
And six journals have not taken any public action.
This month hasn’t been all bad for Carlo Croce. Despite issuing two corrections and being the subject of a lengthy New York Times article about how he’s dodged misconduct accusations for years (prompting his institution to re-open an investigation), Croce is now the recipient of a prestigious award from the American Association for Cancer Research.
In a recent news release, the AACR announced it was bestowing Croce the 11th Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, named after the CEO of the AACR, for his work in the field.
According to the news release:
Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.
The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.
As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.
According to the notice, Yin and five of her co-authors agreed to the retraction:
Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.
One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.
Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Read the rest of this entry »
A pathology journal is retracting two papers after an investigation at the last author’s institution in Germany found evidence of scientific misconduct.
The notice for both papers cites an investigation involving Regine Schneider-Stock, who studies cancer biology at the Friedrich Alexander-University Erlangen-Nuremberg (FAU). Meanwhile, another 2005 paper that lists Schneider-Stock as the first author was retracted in October, noting evidence of image manipulation.
The most recent retractions, from the American Journal of Pathology, note that FAU declined to provide the journal with details of its investigation beyond a prepared statement:
According to an investigation report released by the ORI last year, all 11 studies co-authored by Girija Dasmahapatra, formerly based at Virginia Commonwealth University (VCU) in Richmond, will either be retracted or corrected. In April, Dasmahapatra lost the first of the 11 papers flagged by the ORI in the journal Leukemia. Earlier this month, a second paper from the list was pulled by Clinical Cancer Research.
Dasmahapatra isn’t the only VCU researcher who’s been busy correcting the literature. All 11 papers mentioned in the ORI report list Steven Grant as last author; Paul Dent is a co-author of nine of these studies. Last month, we reported on a retraction in the Journal of Biological Chemistry (JBC) and a mega-correction in Molecular Pharmacology issued for papers by Grant and Dent due to problems with images. Neither paper included Dasmahapatra as a co-author.
We’ve also previously reported on four other errata for image-related issues for papers by Dent (one of which lists Grant as a co-author). Now, we’ve come across another correction in JBC for the pair, which was published last month.
Pharmaceutical giant Pfizer has announced it plans to retract five papers by a former employee, after an investigation found duplicated images.
As first reported today by Leonid Schneider, Pfizer has asked to retract five papers from the lab of Min-Jean Yin, a cancer researcher. A spokesperson for the company confirmed to us that Yin had been fired:
…Min-Jean Yin’s employment has been terminated as a result of our investigation.
The five papers to be retracted are: Read the rest of this entry »
In May of last year, Stephanie Watkins, who now works at Loyola Medicine, earned one
two retraction, which mentions a review by an investigation committee at the National Institutes of Health. Two of the new notes, published in Cancer Research, mention the review as well, and cite data falsification in a figure as the reason for retraction. Watkins is the only author that did not agree to those retractions.
There may be more changes to the literature — an editor at another cancer journal told us the journal is awaiting a decision from the Office of Research Integrity before deciding what to do with a paper by Watkins, given that she does not agree with the misconduct charges.
We’ll start with a retraction note from Cancer Research:
A paper flagged in an Office of Research Integrity notice more than one year ago has finally been retracted. According to the notice, the paper includes images manipulated by author H. Rosie Xing, a former University of Chicago cancer researcher.
The main conclusions of the paper are affected by the ORI finding, according to the retraction note from Molecular Cancer Therapeutics. But otherwise, the note contains information that was available in the ORI finding, published in December 2014.
“Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment” has been cited seven times, according to Thomson Scientific’s Web of Knowledge — twice since the ORI finding came out.
The retraction note explains which images were affected by the manipulation:
An article about how a COX-2 inhibitor (celecoxib) inhibits growth of prostate cancer in rats is being retracted after the authors were unable to provide an investigation committee at New York University with the backup they were asking for.
When the paper was published in 2003, first author Bhagavathi Narayanan worked at the Institute for Cancer Prevention in New York (also known as the American Health Foundation). But when the institute went broke the next year — thanks partly to lavish salaries and offices, as the New York Post reported — the authors claim they could no longer obtain back up for an image in the paper, once it was questioned years later by NYU, where Narayanan is now based.
Here’s the retraction note, published in Clinical Cancer Research: